hrp0086p1-p201 | Diabetes P1 | ESPE2016

Non-Surgical Treatment of Diazoxide-Resistant of Early Diffuse Hyperinsulinism Using Long-Acting Octreotide, A Somaatostatin Analog: Follow-Up of Six Cases

Mention Karine , El Habbas Maya , Sechter Claire , Cartigny Maryse , Dobbelaere Dries

Background: Early diffuse hyperinsulinism represents a life- and brain-threatening condition. Besides enteral or parenteral additional supply, diazoxide represents the first line treatment. For diazoxide-resistant (DREDHI) patients, ablative surgery exposes to severe local complications, exocrine pancreas insufficiency and diabetes or residual hypoglycaemia.Objective and hypotheses: To evaluate the pros and cons of non-surgical treatment of DREDHI.<p...

hrp0084p2-512 | Pituitary | ESPE2015

Pituitary Function after Mild to Severe Traumatic Brain Injury in Children 2–18-Years-Old: A Prospective Study

Braun Karine , Briet Claire , Toussaint Patrick , Trifunovic Helene Bony , Boudailliez Bernard

Background: In recent years, traumatic brain injury (TBI) has been identified as a significant cause of pituitary dysfunction in children. Paediatric prospective studies are rare especially for mild TBI.Objective and hypotheses: The aim of this present study was to evaluate the frequency of hypopituitarism after mild, moderate and severe TBI in hospitalized children, and determining factors of this deficiency.Method: A prospective ...

hrp0095p1-348 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

A homozygous Y443C variant in the RNPC3 is associated with severe syndromic congenital hypopituitarism and diffuse brain atrophy

Bezen Diğdem , Kutlu Orkide , Mouilleron Stephane , Rizzoti Karine , Dattani Mehul , Guran Tulay , Yeşil Gözde

Context: Biallelic RNPC3 variants have been reported in a few patients with growth hormone deficiency, either in isolation or in association with central hypothyroidism, congenital cataract, neuropathy, developmental delay/intellectual deficiency, hypogonadism and pituitary hypoplasia.Objective: To describe a new case with syndromic congenital hypopituitarism and diffuse brain atrophy due to RNPC3 mutations and to compar...

hrp0086fc13.6 | Management of Obesity | ESPE2016

Treatment for Early Onset and Extreme Obesity in Two POMC Deficient Patients: Successful Weight Loss with the Melanocortin-4 Receptor Agonist Setmelanotide

Kuhnen Peter , Clement Karine , Gottesdiener Keith , Fiedorek Fred , van der Ploeg Lex , Wiegand Susanna , Blankenstein Oliver , Gruters Annette , Krude Heiko

Background: POMC deficiency is an extremely rare monogenetic obesity syndrome generally characterized by early onset hyperphagia, red hair and adrenal insufficiency. So far treatment of obesity and hyperphagia with MSH substitution failed, either due to ineffectiveness or side effects of available MC4R agonists.Objective and hypotheses: We hypothesized that the new MC-4R agonist setmelanotide might be a treatment option in POMC deficient patients.<p ...

hrp0082p3-d3-923 | Pituitary (1) | ESPE2014

Think Histiocytosis X Facing Insipidus Diabetes with Thickened Pituitary Stalk

Lichtenberger-Geslin Lydia , Gourmel Antoine , Sainte-Rose Christian , Trifunovic-Bony Helene , Braun Karine , Boudailliez Bernard , Devoldere Catherine

Background: Insipidus diabetes is a rare disease in pediatric endocrinology.Objective and hypotheses: Facing a thickened pituitary stalk on MRI pituitary, the main diagnosis to mention are: dysgerminoma, histiocytosis, sarcoidosis, and autoimmune hypophysitis. Histiocytosis is a rare and often underdiagnosed cause.Method: We report the case of a teenage girl who presented polyuria–polydipsia syndrome at the age of 14 years con...

hrp0097p1-65 | Fat, Metabolism and Obesity | ESPE2023

Natural history of corpulence in patients carrying heterozygous pathogenic variants in the five major genes of the leptin-melanocortin pathway.

Nicaise Clarisse , Dubern Béatrice , Poitou Christine , Clement Karine , Tounian Patrick , Lemale Julie , COURBAGE Sophie , Le Bihan Johanne

Introduction: The leptin-melanocortin pathway plays a key-role in weight control. Pathogenic variants in the five major genes (LEP, LEPR, POMC, PCSK1, MC4R) are associated with early severe obesity. However, the specific associated phenotype with presence of mono-allelic variants and especially BMI trajectories are not well known.Objective: In order to identify specific profiles, we compared BMI trajectories during the f...

hrp0092fc11.2 | Pituitary, Neuroendocrinology and Puberty Session 2 | ESPE2019

A Novel Minor Spliceosome Defect Associated with Growth Hormone Deficiency (GHD) and Primary Ovarian Insufficiency (POI)

Akin Leyla , Gregory Louise , Buonocore Federica , Group GOSgene , Kurtoglu Selim , Kendirci Mustafa , Burçin Gonen Z. , Lovell-Badge Robin , Rizzoti Karine , Dattani Mehul

Objectives: We describe 5 pedigrees with a novel phenotype including GHD associated with primary ovarian insufficiency (POI) and investigate the underlying molecular basis.Patients and Methods: 6 Turkish patients (5F, 1M) born to 5 consanguineous pedigrees with severe GHD were identified. All females had POI; the male had normal puberty. All had severe postnatal growth retardation (height -4.4 to -8.9 SDS at presentation...

hrp0089rfc10.6 | Late Breaking | ESPE2018

Effect of the Current Treatment of X-Linked Hypophosphatemia During Growth on the Development of Osteoarticular Lesions in the Hyp Mouse Model

Cauliez Axelle , Faraji-Bellee Carole-Anne , Salmon Benjamin , Fogel Olivier , Benoit Aurelie , Schinke Thorsten , Miceli Corinne , Briot Karine , Linglart Agnes , Chaussain Catherine , Bardet Claire

Mineralization defects and paradoxical mineralizing enthesopathies are hallmarks of X-linked Hypophosphatemia (XLH), a rare skeletal disease caused by inactivating mutations in the PHEX gene (Phosphate-regulating endopeptidase homolog, X-linked). The current medical treatment, which consist in oral phosphorus supplementation and active vitamin D analogues, aimed at counteracting consequences of FGF23 excess and is commonly prescribed from early childhood to the end of...

hrp0086p1-p339 | Gonads &amp; DSD P1 | ESPE2016

Global and Sexual Quality of Life in Patients with Rokitanski Syndrome: A Comparative Study Between Surgical vs Non Surgical Management of Vaginal Agenesis in a French Cohort of 130 Patients

Bidet Maud , Cheikhelard Alaa , Christine Louis-Sylvestre , Jean Paniel Bernard , Karine Morcel , Magali Viaud , Amandine Baptiste , Caroline Elie , Yves Aigrain , Michel Polak

Background: Vaginal agenesis (VA) in MRKH syndrome can be managed either by surgery or autodilatations.Objective and hypotheses: To compare different managements of MRKH-VA in terms of quality of life, sexual function, anatomical results and complications.Method: National Multicentric observationnal study including 130 patients older than 18, at least one year after completing VA management, from October 2012 to April 2015. 84 had ...

hrp0094fc2.2 | Fat, Metabolism and Obesity | ESPE2021

Phase 3 Trial of Setmelanotide in Participants With Bardet-Biedl Syndrome: Placebo-Controlled Results

Argente Jesus , Clement Karine , Dollfus Helene , Han Joan , Haqq Andrea , Martos-Moreno Gabriel , Mittleman Robert , Stewart Murray , Webster Matt , Yanovski Jack , Yuan Guojun , Haws Robert ,

Background: In a Phase 3 trial in participants with obesity due to Bardet-Biedl syndrome (BBS) and Alström syndrome, setmelanotide was associated with significant reduction from baseline in body weight and hunger at Week 52 (primary endpoint), with outcomes driven by responses in individuals with BBS.Methods: In the same trial (NCT03746522), individuals with BBS or Alström syndrome were randomized and received ...